» TAFI Immunodepleted Deficient Human Plasma

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS IMMUNODEPLETED DEFICIENT PLASMAS

TAFI Immunodepleted Deficient Human Plasma

Fresh frozen plasmas

Plasma deficient for thrombin activatable fibrinolysis inhibitor (TAFI) assay.

Pooled normal citrated human plasma depleted of TAFI using antibodies directed to TAFI immobilized on agarose beads. Plasma contains 20 mM Hepes.

Reference	6-FDPTAFI-10
Presentation	Kit
Format	10 x 1.0 mL
Quote

Reference	6-FDPTAFI
Presentation	Bottle
Format	1 x 100 mL
Quote

Price list, safety data sheets and notices are accessible to our registered customers.

Reference	Presentation	Format	Quote	Product sheet
6-FDPTAFI-10	Kit	10 x 1.0 mL
6-FDPTAFI	Bottle	1 x 100 mL

Price list, safety data sheets and notices are accessible to our registered customers.

TAFI (Thrombin-activatable fibrinolysis inhibitor) is an enzyme that stabilizes the clot by protecting the clot fibrin from lysis. TAFI is activated by thrombin and its activation is amplified in the presence of thrombomodulin.

Activated TAFI removes the C-terminal lysine and arginine residues of fibrin which are necessary for the binding of t-PA, plasmin and plasminogen to fibrin.

Packaging in plastic cryotubes or in bottles of at least 100 mL.

Frozen, immuno-depleted plasmas are certified to have less than 1% for the deficient factor considered, both for the antigenic and functional assay in haemostasis.
This box is intended for research use

- No bovine additives
- No reconstitution error
- No deterioration of plasmas linked to freeze-drying
- Cryotubes ready to use after thawing (4 min at 37°C).

- 10 cryotubes x 1 mL or 100 mL vial of frozen plasma.

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

HEMOSTASIS COAGULATION RESEARCH DEFICIENT PLASMAS IMMUNODEPLETED DEFICIENT PLASMAS